Association Between Corneal Endothelial Cell Density and Topical Glaucoma Medication Use in an Eye Bank Donor Population.

Cornea

*Department of Ophthalmology, Myongji Hospital, Seonam University College of Medicine, Goyang, Korea;†Department of Ophthalmology and Visual Sciences, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY;‡Department of Ophthalmology, Dankook University College of Medicine, Cheonan, Korea; and§Lions Eye Institute for Transplant & Research, Tampa, FL.

Published: December 2016

Purpose: To evaluate the association between corneal endothelial cell density (ECD) and donor topical glaucoma medication use in an eye bank database.

Methods: Raw eye bank data included 19,159 donors over the period July 2007 to May 2015. Free-text, donor medication lists were retrospectively searched for glaucoma medication. Exclusion criteria were age less than 40 years, history of eye surgery, endothelial trauma, guttae, and cell densities <1000 or >3300/mm. Analysis of covariance was used to test differences in cell density between groups while adjusting for age. Linear regression was used to test the correlation of independent interval variables while adjusting for age.

Results: Twelve thousand one hundred fifty-seven donors were included in the final analysis; 134 were on topical glaucoma medication. The mean ECD for donors not on glaucoma medication and pooled donors on glaucoma medication was 2561 ± 348 and 2516 ± 320 cells/mm, respectively (P = 0.42). Subgroup analysis by medication class resulted in nonstatistically significant differences between ECDs of nonmedicated donors and donors on alpha agonists (P = 0.76), beta blockers (P = 0.90), carbonic anhydrase inhibitors (P = 0.13), cholinergics (P = 0.37), and prostaglandin analogs (P = 0.62). The number of glaucoma medication classes used by donors was not a statistically significant predictor of endothelial density (P = 0.298).

Conclusions: Donors on topical glaucoma medication do not have ECDs statistically significantly lower than donors not on medication.

Download full-text PDF

Source
http://dx.doi.org/10.1097/ICO.0000000000000972DOI Listing

Publication Analysis

Top Keywords

glaucoma medication
32
topical glaucoma
16
cell density
12
eye bank
12
medication
11
donors
9
association corneal
8
corneal endothelial
8
endothelial cell
8
glaucoma
8

Similar Publications

Povidone-iodine (PI) is the standard antiseptic for intravitreal injections (IVIs), while chlorhexidine (CHX) is a potential alternative. The efficacy of PI versus CHX in preventing endophthalmitis remains debated, with studies showing mixed results. To compare the effectiveness of using PI compared with CHX in IVI procedures regarding endophthalmitis rates, culture-positive endophthalmitis rates, and changes in visual acuity.

View Article and Find Full Text PDF

This case study details a 41-year-old male patient with Freeman-Sheldon syndrome (FSS) who presented with ocular hypertension. The intraocular pressure (IOP) in his right eye progressively increased over time, leading to visual field loss, culminating in a diagnosis of juvenile-onset open-angle glaucoma (JOAG). Despite conventional medical therapies, adequate IOP control was not achieved, necessitating his referral to Nagoya City University Hospital.

View Article and Find Full Text PDF

Background: Some studies have suggested that glaucoma may be associated with neurodegeneration and a higher risk of dementia.

Objective: To evaluate whether exposure to different categories of topical glaucoma medications is associated with differential dementia risks in people with glaucoma.

Methods: We used data from Adult Changes in Thought, a population-based, prospective cohort study that follows cognitively normal older adults from Kaiser Permanente Washington (KPWA) until Alzheimer's disease (AD) and related dementia development.

View Article and Find Full Text PDF

Background: Human anterior lens capsules (ALCs) have great potential in the treatment of multiple eye diseases, including corneal ulcers, glaucoma, age-related macular degeneration and macular holes. ALCs are also regarded as promising scaffolds for various ocular cells. Here, we investigated different decellularization methods for removing lens epithelial cells (LECs) that adhered to ALCs.

View Article and Find Full Text PDF

Equitable artificial intelligence for glaucoma screening with fair identity normalization.

NPJ Digit Med

January 2025

Harvard Ophthalmology AI Lab, Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.

Glaucoma is the leading cause of irreversible blindness globally. Research indicates a disproportionate impact of glaucoma on racial and ethnic minorities. Existing deep learning models for glaucoma detection might not achieve equitable performance across diverse identity groups.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!